Skip to main content
SpringerLink
Log in

A Statistical Approach to Clinical Trial Simulations

  • Chapter
  • First Online:
Biopharmaceutical Applied Statistics Symposium

Part of the book series: ICSA Book Series in Statistics ((ICSABSS))

Abstract

Drug development is not for the fainthearted. We have heard repeatedly over the years regarding the process of bringing a new compound to the market, that every delay will add millions of dollars in added expenses and lost revenues.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Beal, S. L., & Sheiner, L. B. (1992). NONMEM user’s guide. San Francisco: NONMEM Project Group, University of California, San Francisco.

    Google Scholar 

  • Bhattaram, V. A., Booth, B. P., Ramchandani, R. P., Beasley, B. N., Wang, Y., Tandon, V., et al. (2005). Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. American Association of Pharmaceutical Scientists Journal, 7, E503–E5122005.

    Google Scholar 

  • Biomarkers Definition Working Group. (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics, 69(3), 89–95.

    Article  Google Scholar 

  • Burman, C. F., Hamren, B., & Olsson, P. (2005). Modelling and simulation to improve decision-making in clinical development. Pharmaceutical Statistics, 4(1), 47–58.

    Article  Google Scholar 

  • Chabaud, S., Girard, P., Nony, P., & Boissel, J. P. (2002). Clinical trial simulation using therapeutic effect modeling: Application to ivabradine efficacy in patients with angina pectoris. Journal of Pharmacokinetics and Pharmacodynamics, 29, 339–363.

    Google Scholar 

  • Chang, M. (2010). Monte Carlo simulation for the pharmaceutical industry: Concepts, algorithms, and case studies. Chapman & Hall/CRC Biostatistics Series.

    Google Scholar 

  • Chang, M. (2014). Adaptive design theory and implementation using SAS and R. CRC Press.

    Google Scholar 

  • Dragalin, V., Bornkamp, B., Bretz, F., Miller, F., Padmanabhan, S. K., Patel, N., et al. (2010). A simulation study to compare new adaptive dose-ranging designs. Statistics in Biopharmaceutical Research, 2, 487–512.

    Article  Google Scholar 

  • Eriksen, S., & Keller, L. R. (1993). A multiattribute-utility-function approach to weighing the risks and benefits of pharmaceutical agents. Medical Decision Making, 13(2), 118–125.

    Article  Google Scholar 

  • Ette, E., Godfrey, C., Ogenstad, S., & Williams, P. (2003). Analysis of simulated clinical trials. In H. Kimko, & S. Duffull (Eds.), Simulation for designing clinical trials: A pharmacokinetic/pharmacodynamic modeling perspective. New York: Marcel Dekker.

    Google Scholar 

  • Food and Drug Administration. (1997). The Food and Drug Modernization Act of 1997, in Code of Federal Regulations Title 21 Part 314 Subpart H.

    Google Scholar 

  • Food and Drug Administration, Guidance for Industry. (2003). Exposure-response relationships—Study design, data analysis, and regulatory applications (pp. 1–25). Rockville, MD.

    Google Scholar 

  • Frison, L., & Pocock, S. J. (1992). Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for design. Statistics in Medicine, 11, 1685–1704.

    Article  Google Scholar 

  • Gao, P., Liu, L., & Metha, C. (2013). Exact inference for adaptive group sequential designs. Statistics in Medicine.

    Google Scholar 

  • Gobburu, J. V. S., & Marroum, P. J. (2001). Utilisation of pharmacokinetic/pharmacodynamic modeling and simulation in regulatory decision-making. Clinical Pharmacokinetics, 40(12), 883–892.

    Article  Google Scholar 

  • Gobburu, J. V. S., & Sekar, V. J. (2002). Application of modeling and simulation to integrate clinical pharmacology knowledge across a new drug application. International Journal of Clinical Pharmacology and Therapeutics, 40(7), 281–288.

    Article  Google Scholar 

  • Graham, G., Gupta, S., & Aarons, L. (2002). Determination of an optimal dosage regimen using a bayesian decision analysis of efficacy and adverse effect data. Journal of Pharmacokinetics and Pharmacodynamics, 29(1), 67–88.

    Article  Google Scholar 

  • Herson, J. (2009). Data and safety monitoring committees in clinical trials. Boca Raton: Chapman & Hall/CRC.

    Book  Google Scholar 

  • Holford, N. H. G. (1990). Concepts and usefulness of pharmacokinetic/pharmacodynamic modeling. Fundamental & Clinical Pharmacology, 4(Suppl. 2), 93S–101S.

    Article  Google Scholar 

  • Holford, N., & Ploeger, B. A. (2010). Clinical trial simulation: A review. Clinical Pharmacology and Therapeutics, 88, 166–182.

    Article  Google Scholar 

  • Holford, N. H. G., Kimko, H. C., Monteleone, J. P. R., & Peck, C. C. (2000). Simulation of clinical trials. Annual Review of Pharmacology and Toxicology, 40, 209–234.

    Article  Google Scholar 

  • Huang, X., & Li, J. (2007). Pharmacometrics: The science of quantitative pharmacology. American Journal of Pharmaceutical Education, 71, 75.

    Article  Google Scholar 

  • Jadhav, P. R., Mehta, M. U., & Gobburu, J. V. S. (2004). How biomarkers can improve clinical drug development. American Pharmaceutical Review, 7(3), 62–64.

    Google Scholar 

  • Jonsson, S., & Karlsson, M. O. (2005). Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drug. European Journal of Pharmaceutical Sciences, 25(1), 123–132.

    Article  Google Scholar 

  • Kimko, H., & Duffull, S. B. (2002). Simulation for designing clinical trials: A pharmacokinetic-pharmacodynamic modeling perspective. CRC Press.

    Google Scholar 

  • Kimko, H., & Peck, C. C. (2010). Clinical trial simulations: Applications and trends. Springer.

    Google Scholar 

  • Lacombe, P. A., Vicente, J. A. G., Pages, J. C., & Morselli, P. L. (1996). Causes and problems of non response or poor response to drugs. Drugs, 51, 552–570.

    Article  Google Scholar 

  • Maronde, R. F., Chan, L. S., Larsen, F. J., Strandberg, L. R., Laventurier, M. F., & Sullivan, S. R. (1989). Underutilization of antihypertensive drugs and associated hospitalisation. Medical Care, 27, 1159–1166.

    Article  Google Scholar 

  • Moore, A., Sellwood, W., & Stirling, J. (2000). Compliance and psychological reactance in schizophrenia. British Journal of Clinical Psychology.

    Google Scholar 

  • Mouksassi, M. S., Marier, J. F., Cyran, J., & Vinks, A. A. (2009). Clinical trial simulations in pediatric patients using realistic covariates: Application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome. Clinical Pharmacology & Therapeutics.

    Google Scholar 

  • Nestorov, I., et al. (2001). Modeling and simulation for clinical trial design involving a categorical response: A phase II case study with naratriptan. Pharmaceutical Research, 18(8), 1210–1219.

    Article  Google Scholar 

  • O’Brien, P. C., Zhang, D., & Bailey, K. R. (2005). Semi-parametric and non-parametric methods for clinical trials with incomplete data. Statistics in Medicine, 24, 341–358.

    Article  MathSciNet  Google Scholar 

  • Ogenstad, S. (1997). Analysis and design of repeated measures in clinical trials using summary statistics. Journal of Biopharmaceutical Statistics, 7(4), 593–604.

    Article  MathSciNet  Google Scholar 

  • Peck, C. C., Rubin, D. B., & Sheiner, L. B. (2003). Hypothesis: A single clinical trial plus causal evidence of effectiveness is sufficient for drug approval. Clinical Pharmacology & Therapeutics, 73, 481–490.

    Article  Google Scholar 

  • Pong, A., & Chow, S. C. (2010). Handbook of adaptive designs in pharmaceutical and clinical development. Taylor & Francis, New York: Chapman and Hall/CRC Press.

    Google Scholar 

  • R Core Team. (2014). R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. [Software] (Version 3.1.1). http://www.R-project.org/.

  • Riggs, M. M., Godfrey, C. J., & Gastonguay, M. R. (2007). Clinical trial simulation: efficacy trial. In E. I. Ette, & P. J. Williams (Eds.), Pharmacometrics: The science of quantitative pharmacology (pp. 881–900). Hoboken, NJ: Wiley.

    Google Scholar 

  • Royston, P., & Parmar, M. K. B. (2002). Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Statistics in Medicine, 21, 2175–2197.

    Article  Google Scholar 

  • Sheiner, L. B. (1997). Learning versus confirming in clinical drug development. Clinical Pharmacology and Therapeutics, 61(3), 275–291.

    Article  Google Scholar 

  • Sheiner, L. B., & Ludden, T. M. (1992). Population pharmacokinetics/dynamics. Annual Review of Pharmacology and Toxicology, 32, 185–209.

    Article  Google Scholar 

  • Sheiner, L., & Melmon, K. (1978). The utility function of antihypertensive therapy. Annals of the New York Academy of Sciences, 304, 112–127.

    Article  Google Scholar 

  • Sheiner, L. B., & Steimer, J.-L. (2000). Pharmacokinetic/pharmacodynamic modeling in drug development. Annual Review of Pharmacology and Toxicology, 40(1), 67–95.

    Article  Google Scholar 

  • Spagnoli, A., Ostino, G., & Borga, A. D. (1989). Drug compliance and unreported drugs in the elderly. Journal of the American Geriatrics Society, 37, 619–624.

    Article  Google Scholar 

  • The International Conference on Harmonization (ICH) http://www.ifpma.org/ich1.html.

  • Wang, W., Hallow, K. M., & James, D. A. (2015). A tutorial on RxODE: Simulating differential equation pharmacometric models in R. American Society for Clinical Pharmacology and Therapeutics. CPT: Pharmacometrics & Systems Pharmacology.

    Google Scholar 

  • Wassmer, G., & Vandemeulebroecke, M. (2006). A brief review on software development for group sequential and adaptive designs. Biometrical Journal, 48, 732–737.

    Article  MathSciNet  Google Scholar 

  • Wathen, J. K., & Thall, P. F. (2008). Bayesian adaptive model selection for optimizing group sequential clinical trials. Statistics in Medicine, 27(27), 5586–5604.

    Article  MathSciNet  Google Scholar 

  • Westfall, P. H., Tsai, K., Ogenstad, S., Tomoiaga, A., Moseley, S., & Lu, Y. (2008). Clinical trials simulation: A statistical approach. Journal of Biopharmaceutical Statistics, 18, 611–630.

    Article  MathSciNet  Google Scholar 

  • Westfall, P. H., Dmitrienko, A., DeSouza, C., & Tomoiaga, A. (2010). Clinical trials simulation: A publicly available, grid-enabled, GUI-Driven SAS® System. SAS Global Forum 2010, Paper 180-2010.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Statogen Consulting LLC, 1600 Woodfield Creek Drive, #215, Wake Forest, NC, 27587, USA

    Stephan Ogenstad

Authors
  1. Stephan Ogenstad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephan Ogenstad .

Editor information

Editors and Affiliations

  1. Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, Georgia, USA

    Karl E. Peace

  2. School of Social Work & Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA

    Ding-Geng Chen

  3. Boston University, Cambridge, Massachusetts, USA

    Sandeep Menon

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ogenstad, S. (2018). A Statistical Approach to Clinical Trial Simulations. In: Peace, K., Chen, DG., Menon, S. (eds) Biopharmaceutical Applied Statistics Symposium . ICSA Book Series in Statistics. Springer, Singapore. https://doi.org/10.1007/978-981-10-7829-3_1

Download citation

Publish with us

Policies and ethics

Search

Navigation